Analysts/Institutional Investor Meet/Con. Call Updates

L ACUTAAS CHEMICALS LIMITED A U T (Formerly known as Ami Organics Limited) CIN No. : L24100GJ2007PLC051093 You and us: chemistry’s apex July 28, 2026 To, To, The Corporate Relations Department, The Listing Department BSE LIMITED, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5" Floor, Plot no. C-1, Dalal Street, Fort G-Block, Bandra Kurla Complex, Mumbai- 400 001 Mumbai -400051 Scrip Code: 543349 NSE Symbol: ACUTAAS Dear Sir/Madam, Subject: Transcript of Earnings Call for Q1 FY27 financial results held on July 24, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby enclose the transcript of the Earnings conference call held on July 24, 2026 post announcement of financial results for the quarter ended on June 30, 2026. The same will also be available at the website of Company at www.acutaas.com. This is for your information and records. Yours faithfully, For, ACUTAAS CHEMICALS LIMITED CS Ekta Kumari Srivastava Company Secretary & Compliance Officer Encl: As Above . +9175730 15366, +91 72279 77744 Q Registered Office: Plot No. 440/4, 5 & 6, ¢ info@acutaas.com Road No. 82/A, GIDC Sachin, # www.acutaas.com Dist. Surat- 394230, Gujarat, India “Acutaas Chemicals Limited Q1 FY27 Earnings Conference Call” July 24, 2026 MANAGEMENT: MR. NARESH PATEL – CHAIRMAN AND MANAGING DIRECTOR – ACUTAAS CHEMICALS LIMITED MR. ABHISHEK PATEL – PRESIDENT – STRATEGY – ACUTAAS CHEMICALS LIMITED MR. BHAVIN SHAH – CHIEF FINANCIAL OFFICER – ACUTAAS CHEMICALS LIMITED MODERATOR MR. ARCHIT JOSHI – NUVAMA INSTITUTIONAL EQUITIES Page 1 of 15 Acutaas Chemicals Limited July24, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Acutaas Chemicals Limited Q1 FY27 Earnings Conference Call hosted by Nuvama Institutional Equities. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. I now hand the conference over to Mr. Archit Joshi from Nuvama Institutional Equities. Thank you, and over to you, sir. Archit Joshi: Good evening, everyone and thank you for joining us on Acutaas Chemicals' Q1 FY27 Earnings Conference Call. Today, we have with us Acutaas Chemicals management represented by Mr. Naresh Patel, Chairman and Managing Director; Mr. Abhishek Patel, President, Strategy and Mr. Bhavin Shah, Chief Financial Officer. I would now like to invite Mr. Bhavin Shah to initiate proceedings. Over to you, sir, and thank you. Bhavin Shah: Thank you, Archit. Good evening, everyone. We are pleased to welcome you all to our earnings conference call to discuss Q1 FY '27 financials. Please note that a copy of our disclosure is available on the Investors section of our website as well as on the stock exchanges. Please do note that anything said on this call which reflects our outlook towards the future or which could be construed as forward-looking statement must be reviewed in conjunction with the risk that the company faces. The conference call is being recorded and the transcript along with the audio of the same will be made available on the website of the company and exchanges. Please also note that the audio of the conference call is the copyright material of Acutaas Chemicals and cannot be copied, rebroadcasted or attributed in press or media without specific and written consent of the company. Now I would like to hand over the floor to our CMD, Mr. Naresh Patel for his opening statement. Over to you, sir. Naresh Patel: Thank you, Bhavin. Good evening, everyone. I hope you are all doing well. We began the financial year on a turbulent note, driven by geopolitical tensions in the Gulf. While these tensions persist, our team has done a commendable work in securing raw material availability and ensuring supply continuity. The demand environment for our products remains strong as reflected in the quarter's results. We continue to see healthy RFP activity across our CDMO and NCE products. And our R&D team is working around the clock to service this pipeline on time. Within Specialty Chemicals, demand for battery chemicals remain exceptionally strong. I'm pleased to share that we have successfully completed the trial run of our battery chemicals plant and started commercial supply. Demand here is unprecedented, driven by tight global supply and we, therefore, expect a rapid ramp-up over the coming quarters. Page 2 of 15 Acutaas Chemicals Limited July24, 2026 Let me now turn to semiconductor chemicals. What we are seeing is that AI is starting to push CPU demand higher and that's pulling memory chip demand up right along with it. At a time when supply is already tight. To us, this isn't the passing phase. It is a structural phase. As more of the world adopts AI over the coming years, the appetite for CPUs and memory chip will only keep growing. Our ongoing engagement with customers reinforces our conviction that memory chip demand will remain strong. Which, in turn, will drive demand for the materials we manufacture in BFC, and plan to manufacture at Indichem. Turning to our performance for the quarter. We delivered strong revenue of INR329.7 crores, which is growth of 59.1% Y-o-Y. This strong performance reflects the agility of our business model, our ability to adapt quickly to changing environment and keep delivering the products to our customers on time and without compromise. I would also like to complement our team for mitigating the logistical challenges through the quarter. On a different note, I'm delighted to say that we have been certified as a Great Place to Work. This recognition means a great deal to us because it reflects the culture our people have built together. One of trust, collaboration and genuine pride in what we do. Our team is the engine behind everything we achieve. And this certification is proud valuation of their efforts. I'm equally pleased to report that we have received the Responsible Care certification from the Indian Chemical Council. Responsible Care is the chemical industry commitment to the highest standard of safety, health and environment performance. And earnings it reaffirms our results - - resolve to operate responsibly and sustainably even as we grow. To conclude, we have started the new financial year on a strong note and I remain confident of delivering 25% revenue growth for the full year with stable margins. With that, I would now like to hand over to our Vice President of Strategy Abhishek Patel. He will walk you through the detailed business update. Over to you, Abhishek. Abhishek Patel: Thank you, Naresh bhai. Good evening, everyone. Let me share some additional insight into our business performance for the quarter. Starting with Advanced Pharmaceutical Intermediates segment, this segment delivered robust performance with revenue of INR292.7 crores in Q1 FY '27, reflecting a strong year-on-year growth of 76.5%. While CDMO grew strongly year-on-year as we expected, the core Pharmaceutical Intermediates business also delivered a robust growth. This was driven by our top products as well as by a couple of new products that are gaining volume traction. Moving on to the Specialty Chemicals segment. As communicated on our previous earnings call, we are gradually phasing out commodity chemicals from this financial year, replacing them with newer higher-margin products. Revenue stood at INR37 crores for this quarter in this segment, a decline of 10.6% Y-on-Y. Therefore, even though the BFC business recovered strongly, this was offset by decline in commodity chemical business, which is in line with our expectations. It is worth noting that while overall capacity remains largely unchanged, some minor capex is required to align the plant for the new products. As a result, there may be a transition gap betw [Showing first 8,000 characters — download PDF for full document]